ValiRx plc

Articles of Association

Admission Document

TR1 Notification Document [31 Dec 2024]

TR1 Notification Document [02 Jan 2025]

TR1 Notification Document [07 Jan 2025]

TR1-Notification Document [08 January 2025]

TR1-Notification Document [13 January 2025]

TR-1 Notification Document [14 January 2025]

TR-1 Notification Document [15 January 2025]

Corporate Brokers

 Nominated Adviser

Registrars

Solicitors

Auditors

Bankers

AIM Rule 26

Default features description for sign up page.

DM Sans

The following information is disclosed in accordance with Rule 26 of the AIM Rules for Companies.

ValiRx plc is listed on AIM of the London Stock Exchange under the ticker code VAL. There are no restrictions on the transfer of ValiRx’s shares and these are not listed on any other exchange.

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

Find out more about our Leadership team below.

View all Annual & Half Year Reports, Annual General Meeting Notices & Results, & Investor Presentations below. 

ValiRx plc is a company incorporated in the United Kingdom under the Companies Act 1985, it's “principal” place of business is in the United Kingdom.

: Valirx is subject to the UK City Code on Takeovers and Mergers.

The Total Number of AIM Securities in issue with nominal value of 0.1p is 

The information below was last updated on 

The percentage of AIM Securities not in public hands is approximately 23%.

*70,092,341 ordinary share are held by Dr Mark Eccleston personally, 10,807,692 are held by Annette Williams, Dr. Eccleston’s partner and 3,846,154 ordinary shares are held by Oncolytika (a company in which Dr. Eccleston is interested in)

The Board of Directors is committed to applying high standards of corporate governance using the guidance of the QCA Code, revised in April 2018 as devised by the Quoted Companies Alliance.

 sets out ValiRx’s compliance with the ten principles of the QCA Code, displaying how the company complies, and provides links to appropriate disclosures.

These arrangements are also disclosed in our 

These disclosures were last reviewed on the 19-02-2025.